ViiV Healthcare Presents Real-World Data on Long-Acting Therapies for Diverse HIV Patients at Glasgow

ViiV Healthcare, a prominent HIV-focused pharmaceutical company primarily owned by GSK, with Pfizer and Shionogi as shareholders, is poised to present a plethora of new data from its leading HIV treatment and prevention portfolio at HIV Glasgow 2024. This event will be held in Glasgow, Scotland, from November 10 to November 13, 2024. The data, encapsulated in 42 abstracts, will highlight long-acting treatments and two-drug regimens as viable care options amidst the ongoing HIV epidemic.

Dr. Harmony P. Garges, Senior Vice President and Chief Medical Officer at ViiV Healthcare, emphasized the groundbreaking nature of their long-acting options and two-drug regimens. These innovative therapies are significantly transforming the current landscape of HIV treatment and prevention. ViiV Healthcare is continually assessing the real-world responses of diverse populations to their therapies. Studies involving over 10,000 individuals using Vocabria + Rekambys, more than 50,000 on Dovato, and over 1,300 on Apretude contribute to this wealth of data.

At HIV Glasgow 2024, significant findings on the cabotegravir + rilpivirine long-acting treatment (CAB+RPV LA) will be showcased. A comprehensive post hoc analysis pooling data from over 2,500 participants from four major phase 3/3b clinical trials (FLAIR, ATLAS, ATLAS-2M, and SOLAR) will provide insights into virologic outcomes and isolated viraemic events, comparing daily oral HIV treatments and CAB+RPV LA. Additionally, real-world data from a Canadian patient support program will examine adherence and persistence to CAB+RPV LA.

Data on the two-drug regimen dolutegravir/lamivudine (DTG/3TC) will also be presented. The DOLCE study, sponsored by Fundación Huésped, is the first to thoroughly evaluate the efficacy and safety of DTG/3TC in people with HIV with CD4 counts ≤ 200 cells/mm³. Additionally, findings from the phase IV D2ARLING study will compare the efficacy and safety of DTG/3TC against a three-drug regimen in antiretroviral-naïve populations without baseline drug-resistance testing. These studies underscore the importance of these treatments, especially in contexts where baseline drug resistance testing is not feasible.

ViiV Healthcare's presentation will also cover the cost-effectiveness and usage patterns of long-acting HIV prevention. A study from Canada will compare the economic and public-health impact of introducing cabotegravir long-acting (CAB LA) for HIV pre-exposure prophylaxis (PrEP) against daily oral PrEP (TDF/FTC) and no PrEP. Furthermore, findings from the PROTECT survey will highlight differences in interest and intention to use long-acting PrEP among men who have sex with men and heterosexual men and women across 20 European countries.

Advancements in novel mechanisms of action in HIV research will be another focal point. New data from the BANNER study of VH3810109 (N6LS), an investigational broadly neutralising antibody (bNAb), will be revealed. Previous phase IIa proof-of-concept findings indicated that VH3810109 was well-tolerated and effective in people with HIV. The new findings will explore the correlation between baseline phenotypic sensitivity to N6LS and virologic response post-treatment, further solidifying the potential of bNAbs in HIV treatment.

The extensive research and clinical data being presented by ViiV Healthcare at HIV Glasgow 2024 underscore the company's commitment to advancing HIV treatment and prevention. By continually exploring and validating new therapies and approaches, ViiV Healthcare aims to enhance health outcomes and contribute significantly to the global efforts to end the HIV epidemic.